Análisis comparativo de los costos de  la prevención y tratamiento asociados  al cáncer de cuello uterino en  Ecuador

Bernardo José Vega Crespo; Andrés Andrade Galarza; Satiago Dávila Sacoto; Lisseth Ramos Rodríguez; Dayanara Delgado López; Alejandra Neira Vivian; Sven  Muñoz; David Figueroa Campoverde; Rodrigo Mendieta Muñoz; Veronique Verhoeven

doi:10.26871/killcanasalud.v8i1.1489

Authors

Bernardo José Vega Crespo Universidad de Cuenca
Andrés Andrade Galarza Univeridad de Cuenca https://orcid.org/0000-0001-5598-8165
Satiago Dávila Sacoto Univeridad de Cuenca https://orcid.org/0009-0009-4798-2711
Lisseth Ramos Rodríguez Univeridad de Cuenca https://orcid.org/0009-0000-2261-5602
Dayanara Delgado López Univeridad de Cuenca https://orcid.org/0000-0002-8285-328X
Alejandra Neira Vivian Univeridad de Cuenca https://orcid.org/0000-0002-1615-0746
Sven Muñoz Universidad del Azuay https://orcid.org/0000-0001-9985-5989
David Figueroa Campoverde Univeridad de Cuenca https://orcid.org/0000-0002-9814-6168
Rodrigo Mendieta Muñoz Univeridad de Cuenca https://orcid.org/0000-0001-8040-9305
Veronique Verhoeven Universidad de Amberes https://orcid.org/0000-0002-3708-6501

DOI:

https://doi.org/10.26871/killcanasalud.v8i1.1489

Keywords:

Cancer cervical, prevención, tratamiento, costos

Abstract

Cervical cancer is the second leading cause of death due to oncological pathology in Ecuadorian women. Vaccination and early detection have high efficacy in preventing this disease. The costs of treating cervical cancer are high. Objective: To compare the costs per person for cervical cancer prevention versus the treatment of cervical lesions. Methodology: An analysis of therapeutic recommendation and the cost related with to the treatment and prevention based on the cost schedule for the national health system of Ecuador. Results: The investment in prevention varies according to the scheme used. When using the optimal vaccination and screening with cytology, the investment is $395.62 USD. When using the optimal vaccination and human papillomavirus detection scheme, the cost is $761.42 USD. The cost of follow-up for low-grade lesions is $490.7 USD; for high-grade lesions and in situ cancer with outpatient management, it is $685.43 USD. In the case of in situ cancer/Stage IAI/or non-conizable cervixes, the cost reaches $3465.68 USD. For invasive stages I to 2; IB; IIA, it is $23,762.20 USD, and for stages IIB-III-IV, the minimum cost is $28,560.22 USD. Conclusions: The cost of managing advanced and invasive cervical lesions is 10 to 101 times more expensive than prevention per person. The cost for a person with a basic salary of $460 USD would create inequities in access to treatment and survival. The cost per person that the state must cover for the treatment of advanced cervical cancer is much higher than the investment in prevention.

Downloads

Download data is not yet available.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021 May;71(3):209–49.

World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention [Internet]. 2nd ed. Geneva: World Health Organization; 2021 [cited 2021 Nov 8]. Available from: https://apps.who.int/iris/handle/10665/342365

Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet. 2020 Feb;395(10224):591–603.

Internationa Agency for Research in Cance. Internationa Agency for Research in Cancer. Ecuador Fact sheets 2020. [Internet]. IARC; 2021. Available from: https://gco.iarc.fr/today/data/factsheets/populations/218-ecuador-fact-sheets.pdf

World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. Geneva: World Health Organization; 2020 [cited 2021 Nov 8]. Available from: https://apps.who.int/iris/handle/10665/336583

Ngoma M, Autier P. Cancer prevention: cervical cancer. ecancer Journal [Internet]. 2019 Jul 25 [cited 2023 Jul 28]; Available from: https://www.ecancer.org/journal/13/952-cancer-prevention-cervical-cancer.php

Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet. 2020 Feb;395(10224):575–90.

Petrosky E, Jr JAB, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices. 2015;64(11).

Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. 2019;68(32).

Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer Screening: Past, Present, and Future. Sexual Medicine Reviews. 2020 Jan 1;8(1):28–37.

Instituto Nacional del Cáncer NIH. Tratamiento del cáncer de cuello segun estadio. NHI [Internet]. 2023 [cited 2023 Sep 19]; Available from: https://www.cancer.gov/espanol/tipos/cuello-uterino/tratamiento/segun-estadio

Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors: Journal of Lower Genital Tract Disease. 2020 Apr;24(2):102–31.

Nayar R, Wilbur DC, Solomon D. The Bethesda System for Reporting Cervical Cytology. The Bethesda System for Reporting Cervical Cytology. :14.

Salvo G, Odetto D, Pareja R, Frumovitz M, Ramirez PT. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. Int J Gynecol Cancer. 2020 Jun;30(6):873–8.

Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstetrics & Gynecology. 2019 Jul;134(1):49–57.

Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of cervical cancer from a study conducted in India. IJMS. 2020 Dec 22;73:203–11.

Vega Crespo BJ, Neira Molina VA, Flores Salinas MA, Guerra Astudillo GM, Mora Bravo LV, Ortiz Segarra JI. Minireview: Situación actual del cáncer de cuello uterino en Ecuador, 2019. Rev Med HJCA. 2020 Nov 30;12(3):205–11.

Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecologic Oncology. 2008 Sep;110(3):S4–7.

Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011 Dec 1;121(12):4593–9.

Tsu VD, Ginsburg O. The investment case for cervical cancer elimination. Intl J Gynecology & Obste. 2017 Jul;138(S1):69–73.

Ministerio de Salud Púboica del Ecuador. Tarifario para las prestaciones para el sistema nacional de salud [Internet]. Ministrio de Salud Pública del Ecuador; 2019 [cited 2023 Sep 19]. Available from: https://aplicaciones.msp.gob.ec/salud/archivosdigitales/documentosDirecciones/dnn/archivos/AC-00088-2019%20DIC%2010.pdf

Instituto Nacional de Estadísticas y Censos. Anuario de Nacimientos y Defunciones INEC 2022 [Internet]. INEC; 2022 [cited 2024 Jan 22]. Available from: https://www.ecuadorencifras.gob.ec/nacidos-vivos-y-defunciones-fetales/

Bautista-Valarezo E, Vega Crespo B, Maldonado-Rengel R, Espinosa M, Neira V, Verhoeven V. Knowledge and Perceptions about Cervical Cancer and HPV Screening in Women in Rural Areas of Ecuador: A Qualitative Research Study. IJERPH. 2022 Sep 3;19(17):11053.

Vega Crespo B, Neira VA, Ortíz Segarra J, Andrade A, Guerra G, Ortiz S, et al. Barriers and facilitators to cervical cancer screening among under-screened women in Cuenca, Ecuador: the perspectives of women and health professionals. BMC Public Health. 2022 Nov 22;22(1):2144.

Guerrero L Gilma . Encalada C Grecia Arias M Imelda. MORTALIDAD DEL CÁNCER DE CUELLO UTERINO EN MUJERES DE 20 A 50 AÑOS EN EL ECUADOR. Revista Salud y Bienestar Colectivo. 2021;5(2):1-14.

Ortíz-Segarra J, Vega B, Neira VA, Mora-Bravo L, Guerra-Astudillo G, Ortíz-Mejía J, et al. Conocimiento y prácticas de prevención de cáncer de cuello uterino en mujeres con lesiones histopatológicas. Cuenca, Ecuador 2021. MSKN. 2021 Dec 24;12(2):4–10.

Castro-Jiménez MA, Londoño-Cuellar PA, Vera-Cala LM. Asistencia a citología del cuello uterino y sus determinantes en una población rural colombiana, 1998-1999. Rev salud pública. 2006 Dec;8(3):248–57.

Jorge Ybaseta-Medina, Fredy Paccori-Rodrigo, Alicia Vilca-Yange. Factores clínico epidemiológicos del cáncer de cuello uterino en el Hospital Santa María del Socorro. Ica, Perú. RMP [Internet]. 2019 Aug 8 [cited 2024 Jan 22];4(3). Available from: https://revistas.unica.edu.pe/index.php/panacea/article/view/174

Ministerio de Salud Pública del Ecuador M. Estrategia Nacional para la prevención del Cáncer en el Ecuador 2017 [Internet]. MSP; 2017. Available from: https://aplicaciones.msp.gob.ec/salud/archivosdigitales/documentosDirecciones/dnn/archivos/ac_0059_2017.pdf

Organización Mundial de la salud O. Proyecto de estrategia mundial para acelerar la eliminación del cáncer del cuello uterino como problema de salud pública [Internet]. OMS; 2020. Available from: https://webcache.googleusercontent.com/search?q=cache:LzBlZSaAEMAJ:https://www.who.int/docs/default-source/cervical-cancer/cervical-cancer-elimination-strategy-sp53cc141d3daf48f3a20ce8dbca56450a53cc141d3daf48f3a20ce8dbca56450a.pdf%3Fsfvrsn%3Db8690d1a_22%26download%3Dtrue+&cd=4&hl=es&ct=clnk&gl=ec

Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines. 2021 Nov 30;9(12):1413.

Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020 Oct 1;383(14):1340–8.

Bolaños-Díaz R, Tejada RA, Beltrán J, Escobedo-Palza S. Evaluación costo-efectividad de dos alternativas de vacunación para el virus del papiloma humano en la prevención del cáncer cervical uterino. Rev Peru Med Exp Salud Publica. 2016 Aug 16;33(3):411.

Cornejo S, Chevez A, Ozturk M, Vargas O, Behrensen F, Solano L, et al. El Fondo Rotatorio para el acceso a las vacunas de la Organización Panamericana de la Salud: 43 años respondiendo al programa regional de inmunizaciones. Revista Panamericana de Salud Pública. 2023 Apr 25;47:1.

Fernández González L. Implementación de la vacunación contra el virus papiloma humano en Chile: una mirada desde los determinantes sociales de la salud “ingreso” y “género” Rev méd Chile. 2017 Dec;145(12):1605–9.

Velásquez-De Charry LC, Carrasquilla G, Roca-Garavito S. Equidad en el acceso al tratamiento para el cáncer de mama en Colombia. Salud pública Méx. 2009;51:s246–53.

Guimarães EL, Chissaque A, Pecenka C, Debellut F, Schuind A, Vaz B, et al. Impact and Cost-Effectiveness of Alternative Human Papillomavirus Vaccines for Preadolescent Girls in Mozambique: A Modelling Study. Vaccines. 2023 Jun 2;11(6):1058.

Bonanni P, Faivre P, Lopalco PL, Joura EA, Bergroth T, Varga S, et al. The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019). Expert Review of Vaccines. 2020 Nov 1;19(11):1073–83.

Kim Y, Lee E, Lee H. Sexual Double Standard, Dating Violence Recognition, and Sexual Assertiveness among University Students in South Korea. Asian Nursing Research. 2019 Feb;13(1):47–52.

Saslow D, Andrews KS, Manassaram‐Baptiste D, Smith RA, Fontham ETH, the American Cancer Society Guideline Development Group. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA A Cancer J Clinicians. 2020 Jul;70(4):274–80.

Anna Szymonowicz K, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864–78.

Heinonen A, Jakobsson M, Kiviharju M, Virtanen S, Aro K, Kyrgiou M, et al. Role of Colposcopy after Treatment for Cervical Intraepithelial Neoplasia. Cancers. 2020 Jun 24;12(6):1683.

Abreu ALP, Souza RP, Gimenes F, Consolaro MEL. A review of methods for detect human Papillomavirusinfection. Virol J. 2012 Dec;9(1):262.

Salazar KL, Duhon DJ, Olsen R, Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. Journal of the American Society of Cytopathology. 2019 Sep;8(5):284–92.

Crespo BV, Neira VA, Murillo R, Avilés CO. Cytology Versus Molecular Diagnosis of HPV for Cervical Cancer Screening. Comparison of the Diagnostic Properties of Four Tests in a Rural Community of Cuenca Ecuador. espoch [Internet]. 2023 Nov 9 [cited 2024 Jan 10]; Available from: https://knepublishing.com/index.php/espoch/article/view/14422

Herrera Conza EM, Salazar Torres ZK, Espinosa Martín L, Aspiazu Hinostroza KA. Detección oportuna de cáncer cérvico-uterino. revistavive. 2021 Mar 26;3(9):264–74.

Downs LS, Nayar R, Gerndt J, Saslow D, for the American Cancer Society Primary HPV Screening Initiative Steering Committee. Implementation in action: Collaborating on the transition to primary HPV screening for cervical cancer in the United States. CA A Cancer J Clinicians. 2023 Sep;73(5):458–60.

Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, De La Rosa AP, Witlen R. Relación costo-efectividad de las intervenciones preventivas contra el cáncer cervical en mujeres mexicanas. Salud pública Méx. 2008 Apr;50(2):107–18.

Regalado JG, Rosales VQ, Leverone RB. VALORACIÓN ECONÓMICA DEL IMPACTO EN LA MORBIMORTALIDAD DEL CÁNCER CÉRVICOUTERINO “SISTEMA DE SALUD DEL ECUADOR”. 2022;34.

Morocho Romero KA, Villavicencio Romero EJ, Andrade Galarza AF, Roldán Fernández JV. Supervivencia de pacientes con diagnóstico de Cáncer de Cérvix, estadios clínicos IIB-IIIA-IIIB. SOLCA – Cuenca. 2009 - 2013.: Artículo Original. Rev Oncol Ecu. 2020 Apr 30;30(1):53–65.

Bloom DE, Khoury A, Subbaraman R. The promise and peril of universal health care. Science. 2018 Aug 24;361(6404):eaat9644.

Isidean SD, Tota JE, Gagnon JA, Franco EL. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Review of Vaccines. 2015 Jan 2;14(1):119–33.

Agorastos T, Chatzistamatiou K, Tsertanidou A, Mouchtaropoulou E, Pasentsis K, Kitsou A, et al. Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study. Cancer Prev Res. 2019 Oct;12(10):701–10.

Vega Crespo B, Neira VA, Ortíz Segarra J, Rengel RM, López D, Orellana MP, et al. Role of Self-Sampling for Cervical Cancer Screening: Diagnostic Test Properties of Three Tests for the Diagnosis of HPV in Rural Communities of Cuenca, Ecuador. IJERPH. 2022 Apr 12;19(8):4619.

Vega Crespo B, Neira VA, Ortíz S J, Maldonado-Rengel R, López D, Gómez A, et al. Evaluation of Urine and Vaginal Self-Sampling versus Clinician-Based Sampling for Cervical Cancer Screening: A Field Comparison of the Acceptability of Three Sampling Tests in a Rural Community of Cuenca, Ecuador. Healthcare. 2022 Aug 25;10(9):1614.

Ayala MB, Vester JM, Rodríguez Riveros MI. Experiencias personales, familiares y sociales de mujeres que padecen cáncer de cuello uterino. Paraguay 2021. Rev cient estud investig. 2022 Aug 30;11(1):70–84.

Pereira Duarte DDA, Bustamante-Teixeira MT. Social Iniquity and Mortality Related to Breast and Cervical Cancers: an Integrative Review / Iniquidade Social e Mortalidade por Câncer de Mama e Colo do Útero: Uma Revisão Integrativa. R pesq cuid fundam online. 2018 Jul 1;10(3):877–88.

Malo-Serrano M, Malo-Corral N. Reforma de salud en Ecuador: nunca más el derecho a la salud como un privilegio. Rev Peru Med Exp Salud Publica [Internet]. 2014 Dec 2 [cited 2024 Jan 11];31(4). Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/130